Search Results | DrugBank Online

Did you mean pozanicline of abt 001?

Displaying drugs 7901 - 7925 of 8042 in total

ATL-2502

ATL-2502(Colal-Pred) is an old drug (prednisolone metasulphobenzoate, a steroid) with a new delivery system that releases the medication only in the colon. Releasing the drug directly into the colon reduces the potential for significant side effects often experienced with steroid drugs. Colal-Pred is being studied for use in ulcerative colitis.

Investigational

Cenisertib

Cenisertib is an aurora kinase inhibitor.

Investigational

Canertinib

Canertinib is a pan-erbB tyrosine kinase inhibitor which work against esophageal squamous cell carcinoma in vitro and in vivo. Canertinib treatment significantly affects tumour metabolism, proliferation and hypoxia as determined by PET.

Investigational

Fradafiban

Investigational

Alicaforsen

Investigational

Razuprotafib

Razuprotafib, also known as AKB-9778, is a small-molecule inhibitor restoring Tie2 activation by inhibiting VE-PTP.[L27171,L27176] In investigations against diabetes and COVID-19, razuprotafib is self-administered by patients through subcutaneous injection.

Investigational

Opaganib

Opaganib, also known as ABC294640, is a selective sphingosine kinase-2 (SK2) (https://go.drugbank.com/polypeptides/Q9NRA0) inhibitor that is orally administered. This drug has potential anticancer, anti-inflammatory, and antiviral activities, with potential applications in oncology, inflammation, the gastrointestinal system, and COVID-19.

Investigational

Methopterin

Methopterin is thought to have effects on osteoclasts and to inhibit inflammatory bone destruction.

Investigational

SGX-523

A MET receptor tyrosine kinase inhibitor.

Investigational

RAV12

RAV12 is investigated for use/treatment in solid tumors. RAV12 is a solid. RAV12 is a chimeric antibody that recognizes RAAG12, an N-linked carbohydrate antigen found on gastric, colon, pancreatic, prostate, ovarian, breast, and kidney cancer cells.

Investigational

Cariporide

Investigational

TBC-3711

TBC3711 is a next-generation endothelin antagonist that is being studied through oral and intravenous formulations by Encysive Pharmaceuticals.

Investigational

Latiglutenase

Investigational

alpha-Conotoxin VC 1.1

Investigational

Morphine glucuronide

Investigational

REV131

rEV131 is in development for allergic rhinitis, asthma and several inflammatory eye diseases. It is a topically delivered small protein that acts as an anti-inflammatory agent.

Investigational